679405-86-8

Usage

Uses

Used in Pharmaceutical Industry:
(6-CHLORO-4-METHOXYPYRIDAZIN-3-YL)METHANOL is used as a potential candidate for drug development due to its pyridazine core and functional groups, which may contribute to anti-inflammatory, antitumor, and antimalarial properties. The presence of a methanol group also suggests potential solubility and formulation advantages for creating pharmaceutical formulations.
Further research is necessary to explore the full potential uses and properties of (6-CHLORO-4-METHOXYPYRIDAZIN-3-YL)METHANOL, as its specific applications and effectiveness in various therapeutic areas are not yet fully understood.

Upstream product

• 372118-01-9 4,6-dichloro-pyridazine-3-carboxylic acid methyl ester 

Downstream Products

• 679405-22-2 6-Chloro-3-[2-(3-chloro-2,6-difluoro-phenyl)-imidazol-1-ylmethyl]-4-methoxy-pyridazine 
• 679405-25-5 1-{6-[2-(3-chloro-2,6-difluoro-phenyl)-imidazol-1-ylmethyl]-5-methoxy-pyridazin-3-yl}-ethanone 
• 679405-24-4 3-[2-(3-chloro-2,6-difluoro-phenyl)-imidazol-1-ylmethyl]-4-methoxy-6-thiazyl-pyridazine 
• 679405-87-9 6-chloro-3-chloromethyl-4-methoxypyridazine 

Relevant academic research and scientific papers

1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS

Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

C5A RECEPTOR MODULATORS

The present invention relates to derivatives of formula (I) wherein ring A, X, Y, Z, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.

Imidazol-1-ylmethyl pyridazine derivatives

The invention provides imidazol-1-ylmethyl pyridazine derivatives of the formula: 1 that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5, R6 and Ar are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).